COVID-19 and Bacillus Calmette-Guérin: What is the Link?

Paul K Hegarty, John P Sfakianos, Gianluca Giannarini, Andrew R DiNardo, Ashish M Kamat, Paul K Hegarty, John P Sfakianos, Gianluca Giannarini, Andrew R DiNardo, Ashish M Kamat

Abstract

The debate around the role of vaccination with Bacillus Calmette-Guérin has revived right in the time of the Coronavirus disease 19 pandemic. Since Bacillus Calmette-Guérin is one of the most commonly delivered therapies in urology, in this editorial we discuss some points that we think will be of interest and guidance to practicing urologists during this public health emergency.

Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Figures

Fig. 1
Fig. 1
(A) Map of bacillus Calmette-Guérin (BCG) vaccination policy in Europe by country. Red denotes countries without a current BCG vaccination program. Data courtesy of the BCG World Atlas . (B) Screenshot of a heat map of COVID-19 cases in Europe from the European Centre for Disease Prevention Control website on March 22, 2020.

References

    1. Roy A., Eisenhut M., Harris R.J. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ. 2014;349:g4643.
    1. Ratzan K.R., Musher D.M., Keusch G.T., Weinstein L. Correlation of increased metabolic activity, resistance to infection, enhanced phagocytosis, and inhibition of bacterial growth by macrophages from Listeria- and BCG-infected mice. Infect Immun. 1972;5:499–504.
    1. Kleinnijenhuis J., Quintin J., Preijers F. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A. 2012;109:17537–17542.
    1. Kleinnijenhuis J., Quintin J., Preijers F. BCG-induced trained immunity in NK cells: role for non-specific protection to infection. Clin Immunol. 2014;155:213–219.
    1. Arts R.J.W., Moorlag S.J.C.F.M., Novakovic B. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe. 2018;23 89–100.e5.
    1. Daza J., Charap A., Wiklund P.N., Sfakianos J.P. Role of the innate immune system in the development, progression, and therapeutic response of bladder cancer. Eur Urol Focus. In press. .
    1. Leentjens J., Kox M., Stokman R. BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study. J Infect Dis. 2015;212:1930–1938.
    1. European Centre for Disease Prevention and Control. Distribution of COVID-19 cases. .
    1. Worldometer. Countries in the world by population (2020). .
    1. Zwerling A., Behr M.A., Verma A., Brewer T.F., Menzies D., Pai M. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011;8
    1. Bladder Cancer Advocacy Network COVID-19 (novel coronavirus) and bladder cancer: what patients and families need to know.
    1. Ficarra V., Novara G., Abrate A., et al. Urology practice during COVID-19 pandemic. Minerva Urol Nefrol. In press. .
    1. Babjuk M., Burger M., Compérat E., et al. EAU guidelines on non–muscle-invasive bladder cancer. European Association of Urology. .
    1. Golla V., Lenis A.T., Faiena I., Chamie K. Intravesical therapy for non-muscle invasive bladder cancer—current and future options in the age of bacillus Calmette-Guerin Shortage. Rev Urol. 2019;21:145–153.
    1. Kamat A.M., Lerner S.P., O'Donnell M. Evidence-based assessment of current and emerging bladder-sparing therapies for non–muscle-invasive bladder cancer after bacillus Calmette-Guerin therapy: a systematic review and meta-analysis. Eur Urol Oncol. 2020;3:318–340.
    1. Racioppi M., Di Gianfrancesco L., Ragonese M., Palermo G., Sacco E., Bassi P. Chemoablation with intensive intravesical mitomycin C treatment: a new approach for non–muscle-invasive bladder cancer. Eur Urol Oncol. 2019;2:576–583.
    1. Pignot G., Loriot Y., Kamat A.M., Shariat S.F., Plimack E.R. Effect of immunotherapy on local treatment of genitourinary malignancies. Eur Urol Oncol. 2019;2:355–364.
    1. Brooks N., Nagaraju S., Matulay Y., Han X.Y., Kamat A.M. Bacille Calmette-Guérin retains clinically relevant viability for up to 72 hours after reconstitution: implications for clinical practice in times of shortage. Eur Urol Oncol. In press.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj